Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
Join Mergr to view the latest updates and news from San Francisco-based Bay City Capital.
Bay City Capital’s most common sectors for investment are life science (68%) and medical products (17%). The Firm’s most common investment types include venture (63%) and buyout (lbo, mbo, mbi) (24%). In total, Bay City Capital has invested in 13 US states and 4 different countries. Its largest (disclosed) acquisition occurred in 2009 when it acquired Epizyme for $32M.
In the last 3 years, Bay City Capital has exited 6 companies. The Firm’s most common exit type is trade sale (56%). Bay City Capital’s largest (disclosed) exit occurred in 2007 when it sold Reliant Pharmaceuticals for $1.7B.
Join Mergr to view Bay City Capital’s full profile and discover more large private equity firms just like it.
No obligation. Cancel anytime.